

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

HARBOUR
BIOMED
和 鉑 醫 藥 控 股 有 限 公 司
HBM Holdings Limited
(incorporated in the Cayman Islands with limited liability)
(Stock Code: 02142)

CHANGE OF EXECUTIVE DIRECTOR

The Board announces that:

1. Mr. Xiaoxiang Chen has resigned as an executive Director with effect from 5 May 2022; and
2. Dr. Yiping Rong has been appointed as an executive Director with effect from 5 May 2022.

RESIGNATION OF EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Directors**”) of HBM Holdings Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) announces that Mr. Xiaoxiang Chen (“**Mr. Chen**”) has tendered his resignation as an executive Director with effect from 5 May 2022 for the reason of seeking other opportunities in his career development. Following Mr. Chen’s resignation, Dr. Humphrey Gardner, the Chief Medical Officer of the Company, will take over Mr. Chen’s responsibilities in leading the global clinical development of the Company.

Mr. Chen has confirmed that he has no disagreement with the Board. There is no other matter in respect of his resignation that needs to be brought to the attention of the shareholders of the Company (the “**Shareholders**”) or The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Board would like to take this opportunity to express its gratitude to Mr. Chen for his valuable contribution to the Company during his tenure of office.

APPOINTMENT OF EXECUTIVE DIRECTOR

The Board is pleased to announce that with effect from the date of this announcement, Dr. Yiping Rong (“**Dr. Rong**”) has been appointed as an executive Director.

The biographical details of Dr. Rong are set out below.

Dr. Yiping Rong (戎一平), aged 45, is the senior vice president and head of discovery of the Company.

Dr. Rong was an associate scientist at Shanghai Biochip Co., Ltd. between June 2002 and June 2003. He then served as the associate research investigator at Roche R&D Center (China), where he designed and led two oncology projects (tumor antigen target by antibody modality, protein-protein interaction target by peptide or SMI) between January 2009 to September 2012, with his last position as a principal scientist. From September 2012 to July 2014, Dr. Rong served as senior scientist and group leader of Translation Research, Department of Oncology at Janssen Pharmaceutical R&D, Johnson & Johnson, Shanghai Discovery Center. He was in charge of preclinical translational oncology research for liver cancer indication. As biology leader, he also successfully generated the preclinical data package and patient stratification biomarker strategy to support the first Janssen oncology phase I filing in China. In July 2014, he joined Sanofi Asia Pacific R&D Hub, AP TSU Research as an associate director, where he led and managed the early-stage cancer therapeutics projects for liver cancer until he departed from the position in May 2016 to join the Company.

Dr. Rong received his master's degree in Molecular Biology in June 2002 from East China University of Science and Technology & Chinese National Human Genome Center in China and his Ph.D in Pharmacology in May 2008 from Case Western Reserve University in the U.S.A.. Dr. Rong has also been a member of the American Association of Cancer Research.

Dr. Rong has entered into a service agreement with the Company for a term of three (3) years commencing on 5 May 2022 or until the third annual general meeting of the Company after 5 May 2022, whichever is sooner, subject to (i) retirement from office and re-election at the next general meeting of the Company and (ii) retirement by rotation and re-election at least once every three years, in accordance with the articles of association of the Company and the corporate governance code as set out in Appendix 14 of the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”). According to the terms of Dr. Rong's appointment, Dr. Rong will not receive any remuneration in connection with the performance of his duties as an executive Director under the appointment.

Save as disclosed above, as at the date of this announcement, Dr. Rong confirmed that he does not hold (i) other positions with the Company or other members of the Group; (ii) any directorships in any other public companies of which the securities are listed on any securities market in Hong Kong or overseas in the last three years; and (iii) any other major appointments and professional qualifications.

As at the date of this announcement, Dr. Rong has been granted 136,000 restricted shares pursuant to the post-IPO share award scheme adopted by the Company on 23 November 2020 which are held on his behalf by Kastle Limited and he is deemed interested in these shares within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**SFO**”).

Save as disclosed above, as at the date of this announcement, Dr. Rong has confirmed that he does not have any relationship with any Directors, senior management or substantial shareholders or controlling shareholders of the Company, or any interest in the shares of the Company within the meaning of Part XV of the SFO.

Save as disclosed above, the Board is not aware of any other matters relating to the appointment of Dr. Rong that need to be brought to the attention of the Shareholders, nor is there any other information which is required to be disclosed by the Company pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules.

The Board wishes to take this opportunity to extend to Dr. Rong its warmest welcome.

By order of the Board
HBM Holdings Limited
Dr. Jingsong Wang
Chairman and Executive Director

Hong Kong, 5 May 2022

As at the date of this announcement and after the resignation and appointment of Director, the Board comprises Dr. Jingsong Wang and Dr. Yiping Rong as executive directors; Mr. Yu Min Qiu, Mr. Junfeng Wang and Ms. Weiwei Chen as non-executive directors; Dr. Robert Irwin Kamen, Dr. Xiaoping Ye and Mr. Ka Chi Yau as independent non-executive directors.